NITAC-mediated ISGylation of eIF4E2 attenuates GSK3β proline-directed kinase activity, conferring cytoprotection
Journal of Biological Chemistry · 2025-11 · 301 (11) · 110777
DOI: 10.1016/j.jbc.2025.110777 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2025-11. Verfasst von Lan Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: College of Biomedicine and Health, College of Life Science and Technology, Huazhong Agricultural University, Wuhan, China. Hauptthemen laut MEDLINE: Glycogen Synthase Kinase 3 beta, Eukaryotic Initiation Factor-4E, Cytoprotection, Ubiquitins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Eukaryotic translation initiation factor 4E family member 2 (eIF4E2) has recently been identified as an interacting protein of GSK3β and regulates its proline-directed kinase activity. eIF4E2 undergoes ISGylation at K134 and K222, a conserved posttranslational modification mediated by interferon-stimulated gene 15. In this study, we engineered a novel Nanobody-based ISGylation Targeting Chimera (NITAC) tool to specifically activate eIF4E2 ISGylation and investigate its role in the eIF4E2-GSK3β signaling pathway. By integrating eIF4E2-specific nanobodies Nb.30C7 with the catalytic E3 ligase domain HECT from HERC5, we constructed the NITAC (Nb.30C7-HECT). This NITAC tool mediates site-specific ISGylation of eIF4E2, enhancing the eIF4E2-GSK3β interaction and unexpectedly suppressing proline-directed serine/threonine phosphorylation across multiple crucial targets within the eIF4E2-GSK3β pathway. Importantly, NITAC treatment exerted cytoprotection against oxygen-glucose deprivation/reoxygenation stress, a commonly used in vitro model to simulate ischemic conditions in cell cultures. Furthermore, NITAC treatment reduced reactive oxygen species in neurons and microglia and promoted an anti-inflammatory phenotype in microglia by suppressing proline-directed serine/threonine phosphorylation. In summary, we created a novel NITAC to specifically activate eIF4E2 ISGylation, which showed cytoprotective effects under oxygen-glucose deprivation/reoxygenation stress by inhibiting GSK3β proline-directed kinase activity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Biomedicine and Health, College of Life Science and Technology, Huazhong Agricultural University, Wuhan, China.
- Wuhan Huamei Biotech Co., Ltd, Wuhan, China.
- Department of Head and Neck Surgery, Hubei Cancer Hospital, Tongji Medical College, Wuhan, China.
- College of Biomedicine and Health, College of Life Science and Technology, Huazhong Agricultural University, Wuhan, China; Department of Head and Neck Surgery, Hubei Cancer Hospital, Tongji Medical College, Wuhan, China…
Förderung
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Li, L., Gong, J., Liang, H., Yang, Y., Wu, Y., Yin, Z., Wang, A., Luo, S., Chen, J., & Zhang, M. (2025). NITAC-mediated ISGylation of eIF4E2 attenuates GSK3β proline-directed kinase activity, conferring cytoprotection. Journal of Biological Chemistry, 301(11), 110777. https://doi.org/10.1016/j.jbc.2025.110777
Vancouver
Li L, Gong J, Liang H, Yang Y, Wu Y, Yin Z, et al. NITAC-mediated ISGylation of eIF4E2 attenuates GSK3β proline-directed kinase activity, conferring cytoprotection. Journal of Biological Chemistry. 2025;301(11):110777. doi:10.1016/j.jbc.2025.110777
BibTeX
@article{Li2025,
author = {Li, Lan and Gong, Jinjin and Liang, Huiting and Yang, Ying and Wu, Yuanshun and Yin, Ziyi and Wang, Anni and Luo, Shaoxiang and Chen, Jian and Zhang, Min},
title = {NITAC-mediated ISGylation of eIF4E2 attenuates GSK3β proline-directed kinase activity, conferring cytoprotection},
journal = {Journal of Biological Chemistry},
year = {2025},
volume = {301},
number = {11},
pages = {110777},
doi = {10.1016/j.jbc.2025.110777}
}
EUVIMED